Board of Directors

David Fuller

Chairman

Dr David Fuller holds degrees in Medicine and Pharmacy (Uni of Sydney) and has over 20 years international experience in developing and commercialising new therapeutic products in both large and small cap environments.  His R&D experience encompasses all stages of product development and commercialisation including Pre-clinical,  Clinical Development, Regulatory Approval, product launch and on-market support (Medical Affairs).   David has had direct leadership roles in four product approvals (US/EU), had multiple FDA and EMEA interactions and has designed and executed numerous Phase I-III studies in diverse geographic territories (US, EU, Asia, South America) for both orphan and major market products.  His diverse therapeutic expertise includes rheumatology/inflammation, renal medicine, oncology, CNS / analgesia, dermatology, gastroenterology and infectious disease products across small and large molecule, drug delivery and antibody platforms.

Most recently David was Chief Medical Officer for the Arana Therapeutics (Australia) where he successfully established the medical and clinical function, secured the company’s maiden IND, designed and executed 5 Phase I-II clinical trials and helped transition the company to become a successful takeover target (Cephalon Inc, Augst 2009). David also has strong commercial management and oversight experience from successfully managing his own businesses as well as participating in senior management of publically listed companies (CeNeS (UK), Orphan Medical (US), Genzyme (UK) and Arana Therapeutics Limited) including Board membership of Genzyme UK Ltd.

Tim Grogan LLB, BSc

Chief Executive Officer and Director

Tim was appointed Chief Executive Officer in January 2010, following involvement in Dimerix as Chairman.  He is a co-founder and Executive Director of Fusion Life Sciences and is involved in corporate and business development activities with a range of life sciences organizations in the Asia-Pacific region. He was formerly the VP for Commercial Development and Licensing at Starpharma Pty Limited, an ASX listed (ASX:SPL) biotechnology development company based in Melbourne. Tim was a founding director of Dendritic Nanotechnologies Limited based in Michigan and prior to joining Starpharma, he was responsible for Business Development & New Technologies with Monsanto Australia’s agriculture business and was a Director of Ag-seed Research Pty Ltd. He was previously Director, Technology Transfer & Commercialization with Freehill, Hollingdale & Page and established a new technology management business, now known as FTS. Tim graduated from the University of Melbourne with degrees in Science (Chemistry) and Law and practised in commercial and intellectual property law with Corrs Chambers Westgarth.

Matthew Macfarlane BCom, CA, GAICD

Director

Matt has spent 11 years working in mergers & acquisitions throughout Europe with PwC Consulting, Swisscom, Deutsche Telekom and global data-communications company Equant. Matthew led Swisscom’s $300m investment in Malaysia and over US$50m of venture capital investments into early stage start-ups on behalf of Equant. He also led that company’s negotiations for the US$8 billion merger with Global One as part of a majority sale of Equant to France Telecom. Matthew co-founded the Web 2.0 technology start-up, Vibe Capital raising over $2.7m of funding for the business. Vibe launched the niche parenting community Minti in March 2006 and licensed its core technology to US-based GreatSchools.net in 2007. Matt has been CFO of Vibe Capital since its creation. Most recently Matthew co-founded the venture capital business Yuuwa Capital LP which was successful in obtaining access to the Federal Government’s $20m matching Innovation Investment Fund program.

Alistair Murdoch

Director

Dr Murdoch has 26 years experience in the animal health industry. He has technical and commercial experience in the development, registration and commercialisation of pharmaceutical products in the global market. He has held both executive and advisory positions with Novartis, Schering Plough, Chemeq, Spirogene, Scicom Australia, Glycan and NemGenix.

He has tertiary qualifications in veterinary science and business management and his current focus is the commercialisation of Australian technologies across a broad spectrum of areas. He has recently secured a R+D and Licensing Agreement for a Proof of Concept innovation with a major global pharmaceutical company; and previously been involved the raising in excess of $60M venture capital funding.

James Williams BSc (Hons), PhD, MBA

Director

James is a Founder and Investment Director at Yuuwa Capital LP, a venture capital firm based in Western Australia.

James has broad experience initiating and managing health technology companies. As CEO of both public and private companies, he has a strong track record in transitioning academic research projects through to regulatory approvals, production and marketing launches on time and within budget.

James was previously Managing Director of two medical device companies, ASX-listed Resonance Health Ltd and Argus Biomedical Pty Ltd, both of which took their products to market under his guidance.  He is also a co-Founder and former CSO and Director of iCeutica, Inc., a clinical stage nano drug reformulation company. He was CEO of Dimerix prior to establishing Yuuwa Capital.